Nasdaq GlobeNewswire

Integra LifeSciences Completes the Acquisition of Codman Neurosurgery Business from Johnson & Johnson

Del

PLAINSBORO, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, announced today that it has completed the previously announced acquisition of the Johnson & Johnson Codman Neurosurgery business for approximately $1.045 billion less customary adjustments, enhancing Integra's position as a leading global provider of neurosurgical products.

"The addition of Codman Neurosurgery expands our global leadership position by creating one of the broadest medical device portfolios in the neurosurgery market," said Peter Arduini, Integra's president and chief executive officer. "Our planned investments in product innovation and global infrastructure will allow us to provide more healthcare solutions to surgeons and their patients worldwide."

Integra expects it will complete the previously announced divestiture of certain neurosurgery assets, including Integra's global Camino® ICP monitoring product line, the U.S. rights relating to Integra's fixed pressure shunts, as well as U.S. rights to Codman's DURAFORM®, standard EVD catheters and CSF collection systems, to Natus Medical in the coming days.  The foregoing divestiture is being made as a result of regulatory reviews by the U.S. Federal Trade Commission and the National Markets and Competition Commission of Spain.

"The Codman acquisition is transformational to Integra and creates significant long-term growth opportunities for our entire company," said Mr. Arduini. "We are excited to welcome our new colleagues from around the world into the Integra organization."

Bank of America Merrill Lynch acted as exclusive financial advisor and Latham & Watkins LLP acted as legal advisor to Integra.

About Integra

Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.

Forward Looking Statements

This news release contains "forward-looking statements", including statements regarding the proposed transaction and the ability to consummate the proposed transaction. Statements in this document may contain, in addition to historical information, certain forward-looking statements. Some of these forward-looking statements may contain words like "believe," "may," "could," "would," "might," "possible," "should," "expect," "intend," "plan," "anticipate," or "continue," the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements in this document include without limitation statements regarding the planned integration and performance of the Codman Neurosurgery business. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to the following: statements regarding the anticipated benefits of the Acquisition; and the effects of disruption caused by the Acquisition making it more difficult for the Company to execute its operating plan effectively or to maintain relationships with employees, vendors and other business partners; stockholder litigation in connection with the Acquisition; the Company's ability to successfully integrate the Codman Neurosurgery and other acquired businesses; global macroeconomic and political conditions; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; physicians' willingness to adopt and third-party payers' willingness to provide reimbursement for the Company's and the Codman Neurosurgery's existing, recently launched and planned products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; and other risks and uncertainties discussed in the Company's filings with the SEC, including the "Risk Factors" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent quarterly reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law. All forward-looking statements in this document are qualified in their entirety by this cautionary statement.

Media Contact:
Laurene Isip
609-750-7984
Laurene.isip@integralife.com

Investor Relations Contact: 
Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Integra LifeSciences Holdings Corp. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Clinical data demonstrates significantly increased cure rates using Resistance Guided Therapy for treating the STI Superbug M. genitalium21.6.2018 09:00Pressemelding

SpeeDx ResistancePlus® MG test supports new STI management guidelines SYDNEY, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced clinical data contained in a new study published in the June 2018 issue of Clinical Infectious Diseases 1 [link ] supports the use of Resistance Guided Therapy for more effective treatment of Mycoplasma genitalium infections. Using the SpeeDx ResistancePlus® MG test, the authors recorded an overall cure rate of >92%, a significant increase compared with previous cure rates of 67% prior to using Resistance Guided Therapy.ResistancePlus MG test simultaneously detects the sexually transmitted infection (STI) M. genitalium and the genetic markers linked to antimicrobial resistance (AMR). The test is CE marked and in use across Europe, and available in laboratories across Australia and New Zealand. Clinical trials are underway in the U.S. in preparation for de novo clearance for the test with the U.S. Food and Drug Administration. "This

LM Industries Brings Manufacturing Into the Future as World's First Digital OEM20.6.2018 18:00Pressemelding

The creators of autonomous shuttle Olli form LM Industries, a company designing and building future-looking products with partners like Allianz, Airbus and the United States Marine Corps SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Today, the creators of the Rally Fighter and Olli announced the formation of LM Industries Group, Inc., a technology-enabled manufacturer focused on mobility products headquartered in San Francisco. LM Industries is the world's first digital OEM - which can take concepts to deployed products in under one year, all on its unique digital thread. It brings products to market in an entirely new way, designing with its global community of experts, and applying technology such as 3D printing to create and assemble products in small batches at agile microfactories. The process challenges the century-long dependency on mass manufacturing which has failed to keep up with the modern pace of technological innovation. LM Industries creates transportation, accessibil

Anglo American, Milliken & Company, MOL Group, Koch Industries, Goldcorp and AccorHotels among the Excellence Award winners at Enablon's Sustainable Performance Forum20.6.2018 17:15Pressemelding

Enablon recognizes companies for effectively leveraging technology to improve their sustainability performance CHICAGO, June 20, 2018 (GLOBE NEWSWIRE) -- Enablon, a Wolters Kluwer business and the world's leading provider of EHS, Operational Risk Management and Sustainability Software, announced today the winners of the 2018 Enablon Excellence Awards. The awards were given during a gala dinner at the Sustainable Performance Forum (SPF) in Chicago, and in Paris. The Enablon Excellence Awards recognize organizations that are leading the way within their industry and that effectively leverage technology to improve their sustainability performance to benefit their business, and also their employees, customers and the communities in which they operate. The 2018 Excellence Awards winners are: Enablon Excellence Award in EHS Performance: Koch Industries (Americas) & MOL Group (EMEA) Enablon Excellence Award in Governance, Risk & Compliance (EMEA): AccorHotels Enablon Excellence Award in Integ

Datameer Named Leader in Ovum Self-Service Data Prep Decision Matrix20.6.2018 15:40Pressemelding

Datameer ranked among top vendors for integration and exploration, data manipulation, data governance, and administration SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Datameer, the leader in big data management for analytics, is pleased to announce that it was named a leader in the Ovum Decision Matrix, Selecting a Self-Service Data Prep Solution, 2018-2019, ahead of Alteryx, Datawatch and Oracle. The report highlights Datameer as "a broad and complex platform [..] focused on building and managing data pipelines that enable data to be fed into any analytic tool." "In the self-service data prep market, we're increasingly seeing the trend of 'platformization' of products, whereby data prep becomes a feature rather than a stand-alone tool," said report author Paige Bartley, senior analyst at Ovum. "Datameer has taken this approach, offering a broad platform focused on data pipelines and self-service enablement. But with a broader platform and functionality comes the need for greater g

Kofax Robotic Process Automation Software Creates Smarter Robots20.6.2018 14:00Pressemelding

Kapow 10.3 Adds Artificial Intelligence, Machine Learning and Other Enhancements IRVINE, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- Kofax ®, a leading supplier of software to automate and digitally transform information intensive processes, today announced the addition of artificial intelligence (AI), machine learning and other capabilities in its Kapow(TM) 10.3 Robotic Process Automation (RPA) software. Kapow, the #originalbot, automates and digitally transforms a wide range of human and information intensive processes across front and back office operations. It allows users to develop and deploy smart robots that mimic human actions while driving continuous improvement using AI and machine learning. Kapow robots interact seamlessly across desktop software, traditional enterprise and browser based systems and web sites, aggregating data, transforming it into actionable information, triggering responses, and communicating with other applications. Kapow 10.3 leverages AI and machine lear

CNP Assurances: Pre Stabilisation Notice20.6.2018 13:41Pressemelding

PARIS, June 20, 2018 (GLOBE NEWSWIRE) -- EURONEXT PARIS: CNP 20 th June 2018 CNP Assurances Stabilisation Notice HSBC (contact: 'Syndicate desk'; telephone: +44 207 992 8066) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities The securities: Issuer: CNP Assurances Guarantor (if any): Aggregate nominal amount: EUR Bmk Description: EUR Perpetual Fixed Rate Resettable Restricted Tier 1 Notes Offer price: TBC Other offer terms: Stabilisation: Stabilising Manager(s): Credit Suisse / HSBC (B&D) / Morgan Stanley / Natixis / SG CIB / Unicredit Stabilisation period expected to start on: 20th June 2018 Stabilisation period expected to end no later than: 20th July 2018 Existence, maximum size & conditions of use of over-allotment facility: 5% of the aggregate nominal amount Stabilisation Venue(s) Over the counter (OTC) In connection with the offer of the above securities, the Stabilisation Manager(s)

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom